Acorda Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (23)

Latest Posts

About This Stock More About This Stock
New Hope For Acorda Therapeutics In 2019
Article By: Nascent Trader
Monday, January 28, 2019 4:00 PM EDT
I recommend long Acorda Therapeutics (ACOR) for 1-3 months aiming at a price target zone ranging from $20.23-$27.24 (currently trading at $15.95). The negative impact of generics erosion on Ampyra's sales has been overstated in my opinion.
In this article: ACOR Also: ALKS, MYL, BIIB, ABBV
Read
ACOR And Volatility Go Hand In Hand
Article By: Anna Coulling
Tuesday, September 18, 2018 11:29 AM EDT
When selecting stocks for day trading one of the many factors to consider is how volatile the stock may be both in terms of implied and historic volatility.
In this article: ACOR
Read
Acorda Discontinues Tozadenant Development Program
Article By: The Fly
Monday, November 20, 2017 8:01 AM EDT
Acorda Therapeutics announced that it is discontinuing its clinical development program for tozadenant, an investigational treatment for Parkinson's disease.
In this article: ACOR
Read
Rayno Biobeat 2017 #1: Biotech Rally Driven By M&A
Article By: Rod Raynovich
Friday, February 10, 2017 4:00 PM EDT
Biogen looking good in here at $275+, up 4.2% over five days, down 2.7% YTD. IBB and XBI​ slight gains.
In this article: ACOR, ALNY, ARRY, IBB, REGN, SGEN, AMGN, BIIB, CLVS, HOLX, XBI, AGIO, BLUE, FMI, TSRO
Read
Acorda Therapeutics Reports Positive CVT-301 Results
Article By: KKD Healthcare Analytics
Thursday, February 9, 2017 12:28 PM EDT
Acorda Therapeutics announced the results from a late-stage clinical trial of the drug candidate, CVT-301.
In this article: ACOR
Read

PARTNER HEADLINES

Latest Tweets for $ACOR

No tweets yet!